Global, regional, and national burden of stroke and its risk factors, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019 by Valery L Feigin (5320574)

Global, regional, and national burden of diabetes from 1990 to 2021, with projections of prevalence to 2050: a systematic analysis for the Global Burden of Disease Study 2021 by Kanyin Liane, Ong

“…By 2050, 89 (43·6%) of 204 countries and territories will have an age-standardised rate greater than 10%. InterpretationDiabetes remains a substantial public health issue. …”
Get full text
Get full text
Get full text

Global, regional, and national stillbirths at 20 weeks' gestation or longer in 204 countries and territories, 1990–2021: findings from the Global Burden of Disease Study 2021 by Comfort, Haley

Get full text
Get full text
Get full text

Measuring routine childhood vaccination coverage in 204 countries and territories, 1980–2019: a systematic analysis for the Global Burden of Disease Study 2020, Release 1 by Natalie C Galles (9715361)

Global, regional, and national burden of hepatitis B, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019 by Brittney S Sheena (9715568)

Measuring universal health coverage based on an index of effective coverage of health services in 204 countries and territories, 1990–2019: a systematic analysis for the Global Bur... by Rafael, Lozano

“…Global ambitions to accelerate progress on UHC service coverage are increasingly unlikely unless concerted action on non-communicable diseases occurs and countries can better translate health spending into improved performance. …”
Get full text
Get full text
Get full text

Measuring universal health coverage based on an index of effective coverage of health services in 204 countries and territories, 1990–2019: a systematic analysis for the Global Bur... by Rafael Lozano (234333)

“…Global ambitions to accelerate progress on UHC service coverage are increasingly unlikely unless concerted action on non-communicable diseases occurs and countries can better translate health spending into improved performance. …”

Luspatercept's use in a patient with transfusion‐dependent beta‐thalassemia and intrathoracic extramedullary hematopoiesis (EMH) by Mohammed Najdat Seijari (17563263)

“…While also highlighting the benefits of using luspatercept regarding decreasing the iron overload and improving hemoglobin levels and examining how it was used safely to manage a transfusion‐dependent thalassemia patient with an extramedullary hematopoiesis mass with no adverse events of note.…”